Top

17-05-2018 | Gestational diabetes | Article

Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial

Journal: Acta Diabetologica

Authors: Federica Fraticelli, Claudio Celentano, Isaia AL Zecca, Giacoma Di Vieste, Basilio Pintaudi, Marco Liberati, Marica Franzago, Marta Di Nicola, Ester Vitacolonna

Publisher: Springer Milan

Abstract

Aims

Gestational diabetes mellitus (GDM) is the most common metabolic disorder of pregnancy. The aim of the study is to compare the effect of different dosages of inositol stereoisomers supplementation on insulin resistance levels and several maternal-fetal outcomes in GDM women.

Methods

Participants were randomly allocated to receive daily: 400 mcg folic acid (control treatment), 4000 mg myo-inositol plus 400 mcg folic acid (MI treatment), 500 mg d-chiro-inositol plus 400 mcg folic acid (DCI treatment) or 1100/27.6 mg myo/d-chiro-inositol plus 400 mcg folic acid (MI plus DCI treatment). The homeostasis model assessment of insulin resistance (HOMA-IR) was measured at the diagnosis of GDM and after 8 weeks of treatment. Secondary outcomes, obstetric outcomes and any maternal or fetal complication at delivery were also collected.

Results

Eighty GDM women were assigned to one of the four arms of study (20 per arm). A significant delta decrease in HOMA-IR index was found in subjects of MI group without insulin therapy compared to control group (p < 0.001). A lower variation in average weight gain (at delivery vs pre-pregnancy and OGTT period) was detected in MI group vs control group (p = 0.001 and p = 0.019, respectively). Moreover, women exposed to MI and MI plus DCI required a significantly lower necessity of an intensified insulin treatment. Women of the control group had newborns with higher birth weight compared with women treated with inositol (p = 0.032).

Conclusions

Our study provides interesting but preliminary results about the potential role of inositol stereoisomers supplementation in the treatment of GDM on insulin resistance levels and several maternal-fetal outcomes. Further studies are required to examine the optimal and effective dosages of different inositol supplements.

Clinical trial reg. no.

NCT02097069, ClinicalTrial.gov.

American Diabetes Association (ADA) (2018) Standards of Medical Care in Diabetes-2018. Diabetes Care 41(Suppl 1):S13–S27CrossRef

Di Cianni G, Miccoli R, Volpe L, Lencioni C, Del Prato S (2003) Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes Metab Res Rev 19(4):259–270CrossRefPubMed

Chiefari E, Arcidiacono B, Foti D, Brunetti A (2017) Gestational diabetes mellitus: an updated overview. J Endocrinol Investig 40(9):899–909CrossRef

Casey BM, Lucas MJ, Mcintire DD, Leveno KJ (1997) Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol 90(6):869–873CrossRefPubMed

Jovanovic L, Pettitt DJ (2001) Gestational diabetes mellitus. JAMA 286(20):2516–2518CrossRefPubMed

Croze ML, Soulage CO (2013) Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95(10):1811–1827CrossRefPubMed

Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340(17):1314–1320CrossRefPubMed

Murphy A, Shamshirsaz A, Markovic D, Ostlund R, Koos B (2016) Urinary excretion of myo-inositol and d-chiro-inositol in early pregnancy is enhanced in gravidas with gestational diabetes mellitus. Reprod Sci 23(3):365–371CrossRefPubMed

Matarrelli B, Vitacolonna E, D’Angelo M et al (2013) Effect of dietary myoinositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 26(10):967–972CrossRefPubMed

10.

D’Anna R, Scilipoti A, Giordano D et al (2013) Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes. Diabetes Care 36(4):854–857CrossRefPubMedPubMedCentral

11.

D’Anna R, Di Benedetto A, Scilipoti A et al (2015) Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women. Obstet Gynecol 126(2):310–315CrossRefPubMed

12.

Santamaria A, Di Benedetto A, Petrella E et al (2016) Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med 29(19):3234–3237PubMed

13.

Farren M, Daly N, McKeating A, Kinsley B, Turner MJ, Daly S (2017) The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care 40(6):759–763CrossRefPubMed

14.

Malvasi A, Kosmas I, Mynbaev OA et al (2017) Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients? Clin Ter 168(4):e240–e247PubMed

15.

Corrado F, D’Anna R, Di Vieste G et al (2011) The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 28(8):972–975CrossRefPubMed

16.

Di Biase ND, Martinelli M, Florio V, Meldolesi C, Bonito M (2017) The effectiveness of d-chiro inositol treatment in gestational diabetes. Diabetes Case Rep 2:131CrossRef

17.

Maurizi AR, Menduni M, Del Toro R et al (2017) A pilot study of d-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol 54(4):361–365CrossRefPubMed

18.

International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG et al (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33(3):676–682CrossRefPubMedCentral

19.

ACOG. Committee opinion (2002) Number 267, January 2002: exercise during pregnancy and the postpartum period. Obstet Gynecol 99:171–173CrossRef

20.

Bertolotto A, Lencioni C, Volpe L, Di Cianni G (2007) Rassegna “Attività fisica e diabete gestazionale”. G It Diabetol Metab 27:75–81

21.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed

22.

Galtier-Dereure F, Boegner C, Bringer J (2000) Obesity and pregnancy: complications and cost. Am J Clin Nutr 71(Suppl. 5):1242S–1248SCrossRefPubMed

23.

Celentano C, Matarrelli B, Mattei PA, Pavone G, Vitacolonna E, Liberati M (2016) Myo-inositol supplementation to prevent gestational diabetes mellitus. Curr Diab Rep 16(3):30 (Review)CrossRefPubMed

24.

Huvinen E, Eriksson JG, Koivusalo SB et al (2018) Heterogeneity of gestational diabetes (GDM) and long-term risk of diabetes and metabolic syndrome: findings from the RADIEL study follow-up. Acta Diabetol. https://doi.org/10.1007/s00592-018-1118-y PubMedCrossRef

25.

Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M (2016) A combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol 2016:3204083

26.

Iuorno MJ, Jakubowicz DJ, Baillargeon JP et al (2002) Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 8(6):417–423CrossRefPubMed

27.

Di Biase N, Balducci S, Lencioni C et al (2017) Attività fisica nella gravidanza di donne con diabete. “Il Diabete” 29(2):209–222

28.

Di Biase N, Balducci S, Lencioni C et al (2017) Attività fisica nella gravidanza di donne con diabete, Physical activity in pregnant women with diabetes JAMD 20(1):44–54

29.

Handelsman Y, Mechanick JI, Blonde L et al; American Association of Clinical Endocrinologists (2011) Medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 17(Suppl 2):1–53CrossRefPubMed

30.

American Diabetes Association (2011) Standards of medical care in diabetes 2011. Diabetes Care 34(Suppl 1):S11–S61CrossRefPubMedCentral

31.

Kopec JA, Ogonowski J, Rahman MM, Miazgowski T (2015) Patient-reported outcomes in women with gestational diabetes: a longitudinal study. Int J Behav Med 22(2):206–213CrossRefPubMed

32.

Farrar D, Simmonds M, Griffin S et al (2016) The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. Health Technol Assess 20(86):1–348CrossRefPubMedPubMedCentral

33.

Brown J, Crawford TJ, Alsweiler J, Crowther CA (2016) Dietary supplementation with myo-inositol in women during pregnancy for treating gestational diabetes. Cochrane Database Syst Rev 9:CD012048PubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »